|
1
|
American Cancer Society: Cancer Facts
& Figures 2016. American Cancer Society; Atlanta: 2016
|
|
2
|
International Agency for Research on
Cancer: GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and
Prevalence Worldwide in 2012. http://globocan.iarc.fr/Default.aspxAccessed on.
August 22–2016.
|
|
3
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Soria JC, Felip E, Cobo M, Lu S, Syrigos
K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, et al: Afatinib
versus erlotinib as second-line treatment of patients with advanced
squamous cell carcinoma of the lung (LUX-Lung 8): An open-label
randomised controlled phase 3 trial. Lancet Oncol. 16:897–907.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rizvi NA, Mazières J, Planchard D,
Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E,
Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1
immune checkpoint inhibitor, for patients with advanced, refractory
squamous non-small-cell lung cancer (CheckMate 063): A phase 2,
single-arm trial. Lancet Oncol. 16:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh A, Greninger P, Rhodes D, Koopman L,
Violette S, Bardeesy N and Settleman J: A gene expression signature
associated with ‘K-Ras addiction’ reveals regulators of EMT and
tumor cell survival. Cancer Cell. 15:489–500. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mani SA, Guo W, Liao M-J, Eaton EN,
Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et
al: The epithelial-mesenchymal transition generates cells with
properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi
H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, et
al: Mutation of the mouse klotho gene leads to a syndrome
resembling aging. Nature. 390:45–51. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matsumura Y, Aizawa H, Shiraki-lida T,
Nagai R, Kuro-o M and Nabeshima Y: Identification of the human
klotho gene and its two transcripts encoding membrane and secreted
Klotho protein. Biochem Biophys Res Commun. 242:626–630. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kurosu H, Yamamoto M, Clark JD, Pastor JV,
Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M,
Kawaguchi H, et al: Suppression of aging in mice by the hormone
Klotho. Science. 309:1829–1833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Usuda J, Ichinose S, Ishizumi T, Ohtani K,
Inoue T, Saji H, Kakihana M, Kajiwara N, Uchida O, Nomura M, et al:
Klotho predicts good clinical outcome in patients with
limited-disease small cell lung cancer who received surgery. Lung
Cancer. 74:332–337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Usuda J, Ichinose S, Ishizumi T, Ohtani K,
Inoue T, Saji H, Kakihana M, Kajiwara N, Uchida O, Nomura M, et al:
Klotho is a novel biomarker for good survival in resected large
cell neuroendocrine carcinoma of the lung. Lung Cancer. 72:355–359.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Doi S, Zou Y, Togao O, Pastor JV, John GB,
Wang L, Shiizaki K, Gotschall R, Schiavi S, Yorioka N, et al:
Klotho inhibits transforming growth factor-beta1 (TGF-beta1)
signaling and suppresses renal fibrosis and cancer metastasis in
mice. J Biol Chem. 286:8655–8665. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aviel-Ronen S, Rubinek T, Zadok O, Vituri
A, Avivi C, Wolf I and Barshack I: Klotho expression in cervical
cancer: Differential expression in adenocarcinoma and squamous cell
carcinoma. J Clin Pathol. 69:53–57. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wolf I, Levanon-Cohen S, Bose S, Ligumsky
H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP
and Rubinek T: Klotho: A tumor suppressor and a modulator of the
IGF-1 and FGF pathways in human breast cancer. Oncogene.
27:7094–7105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang B, Kim J, Jeong D, Jeong Y, Jeon S,
Jung SI, Yang Y, Kim KI, Lim JS, Kim C and Lee MS: Klotho inhibits
the capacity of cell migration and invasion in cervical cancer.
Oncol Rep. 28:1022–1028. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen B, Ma X, Liu S, Zhao W and Wu J:
Inhibition of lung cancer cells growth, motility and induction of
apoptosis by Klotho, a novel secreted Wnt antagonist, in a
dose-dependent manner. Cancer Biol Ther. 13:1221–1228. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee J, Jeong DJ, Kim J, Lee S, Park JH,
Chang B, Jung SI, Yi L, Han Y, Yang Y, et al: The anti-aging gene
KLOTHO is a novel target for epigenetic silencing in human cervical
carcinoma. Mol Cancer. 9:1092010. View Article : Google Scholar : PubMed/NCBI
|
